Arcturus Therapeutics (ARCT) PT Lowered to $33 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
Go back to Arcturus Therapeutics (ARCT) PT Lowered to $33 at H.C. Wainwright
January 25, 2022 2:30 PM EST
Brookline Capital Markets analyst Kumaraguru Raja lowered the price target on Arcturus Therapeutics (NASDAQ: ARCT) to $93.00 (from $101.00) while maintaining a Buy rating.
Analyst says: "ARCT-154 and ARCT-165 (self-amplifying mRNA vaccines) are effective against SARS-CoV-2 virus variants, including Omicron and Delta. Results from the Phase 1/2... More
January 25, 2022 8:02 AM EST
Arcturus Therapeutics Holdings Inc. (the Company, Arcturus, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced new data from clinical development programs for ARCT-154 and ARCT-165, its investigational, next-generation, self-amplifying mRNA vaccine candidates targeting variants of concern.
This press release features multimedia. View the full release here:... More
January 24, 2022 8:07 AM EST
Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced updated data from clinical development programs for ARCT-154 and ARCT-165, its investigational, next-generation, self-amplifying mRNA vaccine candidates targeting the variants of concern.
We continue to gather highly encouraging data from our next-generation, self-amplifying mRNA vaccine candidates ARCT-154 and ARCT-165 that have now both demonstrated encouraging neutralizing... More
